How to Specify a Negative Pressure Wound Therapy (NPWT) System: A Lot-by-Lot Tender, RFQ & Acceptance Checklist for Pumps, Dressings and Canisters (2026)

What platform lots should an NPWT tender separate, and why mixing them loses you leverage?

A common mistake in medical device procurement is issuing a single, all-inclusive Request for Proposal (RFQ) for Negative Pressure Wound Therapy (NPWT). When a hospital procurement department or regional health authority issues a generic tender for 'NPWT devices and supplies,' incumbent manufacturers leverage proprietary connector interfaces and bundled capital-rental agreements to lock out secondary suppliers. This results in inflated daily rental fees, mandatory minimum consumable orders, and restricted clinical flexibility.⁷⁸

To establish procurement leverage and maintain high clinical standards, public health systems such as the UK National Health Service (NHS Supply Chain) structure NPWT tenders into five distinct platform lots.⁸ This structure enables procurement teams to award contracts based on best-in-class performance for specific clinical environments while maintaining interoperability standards across consumable lines.

Structuring tenders across these five lots prevents single-vendor lock-in. For example, a hospital can select a cost-effective, high-reliability capital pump manufacturer for Lot 1 while sourcing open-architecture dressing kits and canisters under Lot 4 from an OEM supplier. The leverage this unbundling creates is well documented: the HHS Office of Inspector General found that suppliers' acquisition costs for newer NPWT pumps ran far below Medicare's fee schedule, and it specifically recommended that CMS subject NPWT pumps to competitive bidding and inherent-reasonableness price review⁷

Which pump performance and alarm requirements actually map to reported NPWT failures?

When drafting technical specifications for Lot 1 (Acute) and Lot 2 (Portable) pumps, tender committees often copy generic manufacturer brochures. A far more effective and defensible approach is to ground every specification line item in empirical medical device failure modes extracted from regulatory databases.

Under US FDA regulations, powered NPWT pumps fall under product code OMP (Negative Pressure Wound Therapy Powered Suction Pump, 21 CFR 878.4780, Class II).¹ Related regulatory categories include QFC (NPWT for Reduction of Wound Complications, 878.4783) and non-powered systems under QPX or OKO (878.4683).¹ Analysis of FDA openFDA 510(k) records shows 235 NPWT clearances on file (214 under OMP alone) — a crowded, commoditized field led by KCI/3M, Smith & Nephew, Genadyne, Medela and Cork Medical.²

A systematic review of FDA MAUDE adverse event reports for NPWT systems (189 reports in the 2025–2026 snapshot: 130 injuries, 53 malfunctions, and 6 deaths) alongside 68 device recall records highlights recurring clinical and mechanical failure modes.³⁴ It is vital to note that MAUDE data represents passive surveillance; report counts do not establish incidence, prevalence, comparative safety, or direct causation.³ However, these reports provide invaluable insight into what mechanical safeguards an RFQ must mandate.

By converting these empirical failure modes directly into pass/fail technical criteria in your tender document, procurement officers eliminate low-quality, unverified equipment before the commercial evaluation phase.

What must an NPWT dressing, canister and connector specification require?

While the vacuum pump serves as the active engine, the clinical efficacy of NPWT depends entirely on the physical interaction between the dressing interface, drainage canister, and vacuum tubing. Lot 4 specifications must detail strict material and mechanical tolerances.

1. Wound Contact Foam & Gauze Spec: Tender documents should specify both Polyvinyl Alcohol (PVA) and Polyurethane (PU) foam options. PU foam features an open-cell structure with pore sizes strictly controlled between 400 and 600 µm. This specific pore dimension delivers uniform hydrophobic manifolding of negative pressure across the entire wound bed while promoting healthy granulation tissue formation.¹⁰ PVA foam, by contrast, provides higher tensile strength, hydrophilic moisture retention, and non-adherent properties suitable for sensitive structures, skin grafts, and painful wound beds.¹⁰

2. Semi-Permeable Film Membrane: The polyurethane drape must act as a one-way biological barrier. Specifications must mandate a high Moisture Vapor Transmission Rate (MVTR ≥ 500 g/m²/24h), allowing excess moisture gas to evaporate while preventing external bacterial and viral ingress.

3. Suction Interface Technology: Traditional NPWT tubing inserted directly into the foam under the drape is prone to focal pressure collapse and localized occlusion. Modern tenders should mandate side-suction multi-chamber technology (such as the S.O.M.T multi-port structure).¹⁰ Multi-chamber designs maintain parallel drainage channels, ensuring uninterrupted fluid evacuation even if one port experiences localized blockages from viscous exudate or blood clots.

4. Canister Mechanical Integrity & Gelation: Canisters must be molded from rigid, high-impact polycarbonate or ABS plastic capable of withstanding negative pressures up to -500 mmHg without wall flexing or volumetric deformation. Canisters must incorporate an internal solidifying agent (gelling powder) that turns liquid exudate into a stable gel upon contact, minimizing biohazard spill risks during canister disposal and hospital transport.

What regulatory, UDI and evidence-pack requirements belong in every NPWT RFQ?

A high-scoring commercial proposal is worthless if the supplier cannot provide a complete, audit-ready regulatory evidence pack. To ensure total market compliance and eliminate legal liability, every NPWT RFQ must mandate the submission of a six-part technical evidence pack prior to bid acceptance.

1. Jurisdictional Market Authorizations: For US tenders, valid FDA 510(k) clearance letters under product codes OMP, QFC, or QPX.¹² For European and UK tenders, EU Medical Device Regulation (MDR 2017/745) Class IIa/IIb CE Certificates issued by an accredited Notified Body. For Chinese tenders, NMPA Class II Medical Device Registration Certificates (e.g., Lu Mech Reg. 20182140303).¹⁰
2. Unique Device Identification (UDI) Data: Full compliance with UDI labeling requirements (FDA GUDID / EUDAMED listing), including primary Device Identifier (DI) barcodes, lot numbers, serial numbers, and manufacturing date encoding on all primary and secondary packaging.
3. Sterilization Validation Dossier: Full sterilization validation reports in compliance with ISO 11135 (Ethylene Oxide) or ISO 11137 (Gamma Irradiation), proving a Sterility Assurance Level (SAL) of 10^-6. Residual Ethylene Oxide (EO) levels for foam and dressing kits must be documented below 4 mg/device per ISO 10993-7.
4. Biocompatibility Testing (ISO 10993-1): Certified third-party laboratory test reports establishing biological evaluation of all wound-contact materials, specifically cytotoxicity (ISO 10993-5), intracutaneous reactivity/irritation (ISO 10993-10), and skin sensitization (ISO 10993-10).
5. Electrical & Home Healthcare Safety Compliance: Formal test certificates proving compliance with IEC 60601-1 (General Electrical Safety), IEC 60601-1-2 (Electromagnetic Compatibility), and IEC 60601-1-11 (Requirements for Medical Electrical Equipment Used in the Home Healthcare Environment).
6. Factory Quality Management System (QMS): Valid ISO 13485:2016 certification covering the specific manufacturing facility, scope of design, and sterile medical device production.

Tender guidelines should explicitly state that bids lacking any of these six technical dossiers will be rejected immediately at the preliminary administrative screening stage, prior to any commercial scoring.

How do US HCPCS/CPT and EU/UK tender rules change what you must specify?

Regulatory and reimbursement structures dictate how NPWT systems are ordered, billed, and specified in different international markets. Understanding these regional frameworks is essential for category managers and commercial distributors.

United States (CMS & Payer Billing): In the US Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) environment, coverage is governed strictly by CMS Local Coverage Determination (LCD) L33821 and Local Coverage Article A52511.⁵ Specifications for products intended for US distribution must align with standard HCPCS coding:

• HCPCS E2402: Stationary or portable powered NPWT pump. Medicare limits billing to one pump per beneficiary at any given time.⁵
• HCPCS A6550: Wound dressing set for use with NPWT pump (includes foam/gauze, drape, and tubing). CMS establishes a maximum billing quantity of 15 dressing kits per wound per 30-day period.⁵
• HCPCS A7000: Canister set for use with NPWT pump. CMS establishes a maximum billing quantity of 10 canister sets per 30-day period. Crucially, LCD L33821 mandates that wounds producing high volume exudate (≥90 mL/day) qualify for high-capacity canister billing.⁵
• HCPCS A9272: Disposable/single-use integrated NPWT system. Category managers must note that under current CMS DMEPOS policy, disposable NPWT devices coded A9272 are statutorily non-covered under the Medicare DME benefit, requiring alternative outpatient hospital billing or private payer coding.⁵
• CPT Clinical Application Codes: Clinical procedure coding utilizes CPT 97605 (NPWT surface area ≤ 50 sq cm, including DME setup and dressing application) and CPT 97606 (NPWT surface area > 50 sq cm).⁵

Reimbursement audit risks are substantial. CMS Medicare Learning Network (MLN) compliance reporting indicates a 17% improper payment rate for NPWT, resulting in approximately $12.1 million in projected improper annual Medicare payments.⁶ Furthermore, historical HHS Office of Inspector General (OIG) investigations (Report OEI-02-07-00660) recommended that CMS subject NPWT pumps to competitive bidding and inherent reasonableness price adjustments due to high supplier markups.⁷ Tender specifications must therefore mandate rigorous clinical documentation capabilities to support billing audits.

Europe and International Procurement Models: Procurement dynamics across Europe vary widely by jurisdiction, as documented by the European Wound Management Association (EWMA):⁹

• United Kingdom: National procurement is driven by the NHS Supply Chain NPWT Framework (ref 2020/S 141-348143), which enforces the 5-lot structure described above across six awarded commercial suppliers.⁸
• Sweden: Procurement is decentralized across regional county councils (Landsting), which issue multi-year public tenders offering combined purchase, lease, and fee-per-patient-day options.⁹
• Germany: Inpatient hospital NPWT is funded under the G-DRG system, where hospitals typically lease capital pumps and purchase fungible consumables. Outpatient NPWT coverage requires strict Federal Joint Committee (G-BA) evidence compliance.⁹
• Spain: Regional health services manage public tenders, with mandatory public competitive bidding triggered for any annual product category expenditure exceeding €18,000.⁹

How do you build a reusable-vs-disposable and total-cost decision without inventing prices?

Evaluating the Total Cost of Care (TCOC) for NPWT requires comparing durable capital pumps against single-use disposable systems without relying on arbitrary price claims. Procurement models must evaluate cost drivers across four operational dimensions:

By establishing this decision matrix, procurement committees determine the exact clinical crossover point: heavy-exudate inpatient wounds justify the capital and processing overhead of Lot 1/2 reusable pumps, whereas low-exudate closed surgical incisions achieve a lower TCOC using Lot 3 disposable systems.

Where VEMERIX fits—and where due diligence still begins

As the international brand of Weihai Medison Medical Equipment Co., Ltd., VEMERIX delivers a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery, and perioperative care.¹⁰ In the NPWT category, VEMERIX provides registered, evidence-backed hardware and consumable platforms designed to meet international tender requirements.

The VEMERIX NPWT portfolio comprises two core product platforms:

• VEMERIX Medical Vacuum NPWT Pump: Microcomputer-controlled vacuum unit (NMPA Lu Mech Reg. 20182140303). Features continuous and intermittent operating modes, continuously adjustable vacuum pressure from -50 mmHg to -450 mmHg in precise 10 mmHg increments (±0.2% display accuracy), quiet operation (<45 dB), suction flow rate of 1.5–8.0 L/min, and multi-mode power supply (AC/DC, internal battery providing 4 h continuous / 8 h intermittent operation, plus optional 12 V vehicle DC power). Integrated safety protections include gas-leak alarms, overflow alarms, and automatic motor overheat shut-off.¹⁰
• VEMERIX Disposable NPWT Drainage Dressing Kit: Incorporates proprietary S.O.M.T side-suction multi-chamber drainage technology paired with high-purity Polyvinyl Alcohol (PVA) or Polyurethane (PU) foam featuring controlled 400–600 µm pore geometry, biological semi-permeable membrane drape, and quick-connect tubing.¹⁰

For international distributors, procurement engineering teams, and hospital category managers preparing NPWT tenders, VEMERIX provides complete regulatory dossiers, sample evaluation kits, and contract manufacturing/OEM customization options; teams ready to specify or sample can request a technical pack and distributor discussion. Readers are encouraged to review related technical reports on the disposable shift in negative pressure wound therapy¹⁰ and our sterile device contract manufacturing guide¹⁰.

Frequently Asked Questions (FAQ)

Q1: What is the FDA product code for an NPWT pump?
Powered NPWT pumps are categorized under FDA product code OMP (Negative Pressure Wound Therapy Powered Suction Pump, 21 CFR 878.4780, Class II). Systems indicated specifically for reducing wound complications carry product code QFC (21 CFR 878.4783), while non-powered or mechanically powered systems carry product codes QPX or OKO (21 CFR 878.4683).¹

Q2: What pressure range and alarms should an NPWT tender require?
An acute or portable NPWT tender should require a pressure adjustment range from -50 mmHg to at least -450 mmHg in 10 mmHg steps with ≤±0.2% sensor accuracy. Alarms must include audible (≥65 dB) and visual signals for vacuum leak, line occlusion/blockage, canister overflow, low battery, and thermal motor overheat.³¹⁰

Q3: How does the NHS Supply Chain NPWT framework split the category?
The NHS Supply Chain NPWT framework (ref 2020/S 141-348143) divides procurement into five lots: Lot 1 Large Inpatient Pumps, Lot 2 Portable Ambulatory Pumps, Lot 3 Disposable Single-Use Pumps, Lot 4 Open-Supply Consumables & Dressings, and Lot 5 Managed Rental Services.⁸

Q4: Is a disposable NPWT pump covered by US Medicare?
Under current CMS DMEPOS policy (LCD L33821), integrated single-use/disposable NPWT systems coded under HCPCS A9272 are statutorily non-covered under the Medicare DME benefit. Traditional durable pumps (E2402) with separate dressing kits (A6550) and canisters (A7000) remain covered subject to clinical documentation rules.⁵

Q5: What regulatory evidence pack should an NPWT RFQ require from a supplier?
Every RFQ should require a six-part dossier: (1) valid market authorizations (FDA 510(k), EU MDR CE, or NMPA registration); (2) UDI GUDID listing; (3) ISO 11135/11137 sterilization validation (SAL 10^-6); (4) ISO 10993 cytotoxicity and irritation test reports; (5) IEC 60601-1 and IEC 60601-1-11 electrical safety certificates; and (6) ISO 13485 QMS certification.¹¹⁰

Q6: How do I compare reusable vs disposable NPWT on total cost without inventing prices?
Compare total cost across five objective dimensions: upfront capital/rental fees, consumable kit change frequency (A6550 max 15/month), hospital sterile reprocessing and biomedical maintenance overhead, logistics asset-loss risk, and target wound exudate volume (>90 mL/day acute vs <30 mL/day closed incision).⁵⁷